Business Context and Reporting Period
This Form 8-K was filed by Trovagene, Inc. (not Cardiff Oncology, Inc.) on December 14, 2017, reporting events occurring on December 15, 2017. The company is a Delaware corporation headquartered in San Diego, CA.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures. The report focuses exclusively on a capital raising event.
Material Changes
On December 15, 2017, Trovagene, Inc. announced the pricing of a public offering consisting of:
- 15,000,000 shares of common stock (or common stock equivalents).
- Common warrants to purchase up to an aggregate of 15,000,000 shares of common stock.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or specific risk factors beyond the standard disclosure of the offering. The press release detailing the offering is included as Exhibit 99.1.
Investor Verification Checklist
- Verify the final closing date and total net proceeds of the public offering.
- Confirm the exercise price and expiration terms of the 15,000,000 warrants issued.
- Review the underwriting agreement for any lock-up provisions or over-allotment options.
- Check subsequent filings for the actual dilution impact on existing shareholders.